Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer

Biomarkers in Medicine

Volumn 2, Issue 4, 2008, Pages 397-407

  Spears, M ^a   Kenicer, J ^a   Munro, A F ^a   Bartlett, John M S ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Anthracycline; Breast cancer; Endocrine; HER family; Taxane

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GEFITINIB; LAPATINIB; LETROZOLE; METHOTREXATE; PACLITAXEL; PERTUZUMAB; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE I; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL OBSERVATION; CLINICAL TRIAL; COMPETITIVE INHIBITION; DISEASE FREE SURVIVAL; DISEASE MARKER; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; EARLY CANCER; GENE AMPLIFICATION; HUMAN; LYMPH NODE METASTASIS; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT SELECTION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RECURRENCE RISK; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; SURVIVAL TIME;

EID: 54849417399     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.2.4.397     Document Type: Review

References (85)

1. Slamon DJ, Clark GM, Wong SG: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987).
2. Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16(6), 413-418 (1998).
3. Yarden Y, Sliwkowski MX: Untangling the ErbB signaling network. Nat. Rev. Mol. Cell Biol. 2(2), 127-137 (2001).
4. Yarden Y, Baselga J, Miles D: Molecular approach to breast cancer treatment. Semin. Oncol. 31(5), 6-13 (2004).
5. Witton CJ, Reeves JR, Going JG, Cooke TG, Bartlett JMS: Coexpression of EGFr, HER2, HER3 and HER4 in primary human breast carcinoma. Breast Cancer Res. Treat. 69(3), 216 (2001).
6. Zwick E, Bange J, Ullrich A: Receptor tyrosine kinase signaling as a target for cancer intervention strategies. Endocr. Relat. Cancer 8(3), 161-173 (2001).
7. Yarden Y: The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic oppotunities. Eur. J. Cancer 37, S3-S8 (2001).
8. Hynes NE, Horsch K, Olayioye MA, Badache A: The ErbB receptor tyrosine family as signal integrators. Endocr. Relat. Cancer 8(3), 151-159 (2001).
9. Olayioye MA, Neve RM, Lane HA, Hynes NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19(13), 3159-3167 (2000).
10. Klapper LN, Glathe S, Vaisman N et al.: The erbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl Acad. Sci. USA 96(9), 4995-5000 (1999).
11. Graus-Porta D, Beerli RR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16(7), 1647-1655 (1997).
12. Citri A, Skaria KB, Yarden Y: The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp. Cell Res. 284(1), 54-65 (2003).
13. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL: Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl Acad. Sci. USA 91(17), 8132-8136 (1994).
14. Vidal GA, Naresh A, Marrero L, Jones FE: Presenilin-dependent γ-secretase processing regulates multiple ERBB4/HER4 activities. J. Biol. Chem. 280(20), 19777-19783 (2005).
15. Naresh A, Long WW, Vidal GA et al.: The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. Cancer. Res. 66(12), 6412-6420 (2006).
16. Vidal GA, Clark DE, Marrero L, Jones FE: A constitutively active ERBB4// HER4 allele with enhanced transcriptional coactivation and cell-killing activities. Oncogene 26(3), 462-466 (2006).
17. Pianetti S, Arsura M, Romieu-Mourez R, Coffey RJ, Sonenshein GE: Her-2/ neu overexpression induces NF-κB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IκB-α that can be inhibited by the tumor suppressor PTEN. Oncogene 20(11), 1287-1299 (2001).
18. Chu I, Blackwell K, Chen S, Slingerland J: The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer. Res. 65(1), 18-25 (2005).
19. Smith BL, Chin D, Maltzman W, Crosby K, Hortobagyi GN, Bacus SS: The efficacy of herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signaling proteins. Br. J. Cancer 91(6), 1190-1194 (2004).
20. Albanell J, Codony J, Rovira A, Mellado B, Gascon P: Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. N. Trends Cancer 21st Cent. 532, 253-268 (2003).
21. Bayliss J, Hilger A, Vishnu P, Diehl K, El Ashry D: Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin.Cancer Res. 13(23), 7029-7036 (2007).
22. Piccart-Gebhart MJ: Anthracyclines and the tailoring of treatment for early breast cancer. N. Engl. J. Med. 354(20), 2177-2179 (2006).
23. Tovey SM, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JMS: Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin.Cancer Res. 11(13), 4835-4842 (2005).
24. Bartlett JMS, Ellis IO, Dowsett M et al.: Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER)-negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J. Clin. Oncol. 25(28), 4423-4430 (2007).
25. Tovey SM, Dunne B, Witton CJ, Cooke TG, Bartlett JMS: HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4. Breast Cancer Res. 8(2), R19 (2006).
26. Bartlett J, Mallon EA, Forsyth A et al.: HER2 (in the TACT and TEAM trials) differentially affects invasive potential in ER-ve and ER+ve breast cancers. J. Clin. Oncol. 23(16S), 9557 (2005).
27. El-Rehim D, Pinder S, Paish C et al.: Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br. J. Cancer 91, 1532-1542 (2004).
28. Tovey SM, Witton CJ, Bartlett JMS, Stanton PD, Reeves JR, Cooke TG: Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res. 6(3), R246-R251 (2004).
29. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JMS: Expression of the HERI-4 family of receptor tyrosine kinases in breast cancer. J. Pathology 200(3), 290-297 (2003).
30. Miller WR, Bartlett JMS, Canney P, Verrill M: Hormonal therapy for postmenopausal breast cancer: the science of sequencing. Breast Cancer Res. Treat. 103(2), 149-160 (2007).
31. Abe O, Abe R, Enomoto K et al.: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472), 1687-1717 (2005).
32. Howell A, Cuzick J, Baum M et al.: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453), 60-62 (2005).
33. Mouridsen HT, Keshaviah A, Mauriac L et al.: BIG 1-98: a randomized double-blind Phase III study comparing letrozole and tamoxifen given in sequence vs alone as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. J. Clin. Oncol. 24(18), 10S-10S (2006).
34. Coombes RC: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 351(23), 2461 (2004).
35. Coombes RC, Kilburn LS, Snowdon CF: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561), 559-570 (2007).
36. Buzdar AU, Coombes RC, Goss PE, Winer EP: Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 112, 700-709 (2008).
37. Massarweh S, Osborne CK, Creighton CJ et al.: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer. Res. 68(3), 826-833 (2008).
38. Massarweh S, Osborne CK, Jiang S et al.: Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer. Res. 66(16), 8266-8273 (2006).
39. Osborne CK, Shou J, Massarweh S, Schiff R: Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin.Cancer Res. 11(2), 865S-870S (2005).
40. Bartlett JMS: Translational reserach and the development of novel biomakers in breast cancer. Adv. Br. Cancer 3(4), 76-85 (2006).
41. Gutierrez MC, Detre S, Johnston S et al.: Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J. Clin. Oncol. 23(11), 2469-2476 (2005).
42. Paik S, Bryant J, Tan-Chiu E et al.: HER2 and choice of adjuvant chemotherapy for invasive breast cancer: national surgical adjuvant breast and bowel project protocol B-15. J. Natl Cancer Inst. 92(24), 1991-1998 (2000).
43. Ellis MJ, Coop A, Singh B et al.: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J. Clin. Oncol. 19(18), 3808-3816 (2001).
44. Schiff R, Massarweh S, Shou J, Osborne CK: Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin.Cancer Res. 9(1), 447S-454S (2003).
45. Viale G: Central analysis of big 198. (2007) (In press).
46. Dowsett M, Cuzick J, Wale C, Howell T, Houghton J, Baum M: Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J. Clin. Oncol. 23(30), 7512-7517 (2005).
47. Ross JS, Fletcher JA, Bloom KJ et al.: Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol. Cell Proteomics 3(4), 379-398 (2004).
48. Zaczek A, Brandt B, Bielawski KP: The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol. Histopathol. 20(3), 1005-1015 (2005).
49. Castano E, Vorojeikina DP, Notides AC: Phosphorylation of serine-167 on the human oestrogen receptor is important for oestrogen response element binding and transcriptional activation. Biochem. J. 326, 149-157 (1997).
50. Kato S, Masuhiro Y, Watanabe M et al.: Molecular mechanism of a cross-talk between oestrogen and growth factor signaling pathways. Genes Cells 5(8), 593-601 (2000).
51. Nicholson RI, Hutcheson IR, Harper ME et al.: Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr. Relat. Cancer 8(3), 175-182 (2001).
52. Jiang J, Sarwar N, Peston D et al.: Phosphorylation of estrogen receptor-α at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin.Cancer Res. 13(19), 5769-5776 (2007).
53. Balasenthil S, Barnes CJ, Rayala SK, Kumar R: Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Lett. 567(2-3), 243-247 (2004).
54. Santen RJ, Song RX, Zhang ZG, Yue W, Kumar R: Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer. Clin.Cancer Res. 10(1), 337S-345S (2004).
55. Kato S, Endoh H, Masuhiro Y et al.: Activation of the estrogen-receptor through phosphorylation by mitogen-activated protein-kinase. Science 270(5241), 1491-1494 (1995).
56. Benz CC, Scott GK, Sarup JC et al.: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of Mcf-7 cells transfected with Her2/Neu. Breast Cancer Res. Treat. 24(2), 85-95 (1992).
57. Osborne CK, Schiff R: Estrogen-receptor biology: continuing progress and therapeutic implications. J. Clin. Oncol. 23(8), 1616-1622 (2005).
58. Razandi M, Pedram A, Park ST, Levin ER: Proximal events in signaling by plasma membrane estrogen receptors. J. Biol. Chem. 278(4), 2701-2712 (2003).
59. Muss HB, Thor AD, Berry DA et al.: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med. 330(18), 1260-1266 (1994).
60. Pritchard KI, Shepherd LE, O'Malley FP et al.: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 354(20), 2103-2111 (2006).
61. Levine MN, Pritchard KI, Bramwell VHC, Shepherd LE, Tu D, Paul N: Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada clinical trials group trial MA5. J. Clin. Oncol. 23(22), 5166-5170 (2005).
62. Knoop AS, Knudsen H, Balslev E et al.: Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 23(30), 7483-7490 (2005).
63. Di Leo A, Gancberg D, Larsimont D et al.: HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin.Cancer Res. 8(5), 1107-1116 (2002).
64. Di Leo A, Chan S, Paesmans M et al.: HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res. Treat. 86(3), 197-206 (2004).
65. Sharma BK, Ray A, Kaur S, Gupta S: Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumor suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast. Indian J. Exp. Biol. 37(3), 223-237 (1999).
66. Paik S, Bryant J, Park C et al.: erB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl Cancer Inst. 90(18), 1361-1370 (1998).
67. Tanner M, Jarvinen P, Isola J: Amplification of HER-2/neu and topoisomerase IIα in primary and metastatic breast cancer. Cancer. Res. 61(14), 5345-5348 (2001).
68. Cardoso F, Durbecq V, Larsimont D et al.: Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-α gene amplification and protein overexpression in locally advanced/ metastatic breast cancer. Int. J. Oncol. 24(1), 201-209 (2004).
69. Shen WH, Balajee AS, Wang J et al.: Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128(1), 157-170 (2007).
70. Huang W, Chang HY, Fei T, Wu H, Chen YG: GSK3β mediates suppression of cyclin D2 expression by tumor suppressor PTEN. Oncogene 26(17), 2471-2482 (2006).
71. Tzaida O, Gogas H, Dafni U et al.: Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Oncology 72(5-6), 388-396 (2007).
72. Bartlett JMS, Munro AF, Cameron DA, Thomas JS, Prescott RJ, Twelves C: Type I receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J. Clin. Oncol. (2008) (In Press).
73. Hayes DF, Thor A, Dressler L et al.: HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. J. Clin. Oncol. 24(18), 5S-5S (2006).
74. Hayes DF, Thor AD, Dressler LG et al.: HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med. 357(15), 1496-1506 (2007).
75. Konecny GE, Thomssen C, Luck HJ et al.: HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J. Natl. Cancer Inst. 96(15), 1141-1151 (2004).
76. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B: HER-2 and topoisomerase II as predictors of response to chemotherapy. J. Clin. Oncol. 26(5), 736-744 (2008).
77. Azambuja E, Durbecq V, Rosa DD et al.: HER-2 overexpression/ amplification and its interaction with taxane-based therapy in breast cancer. Ann. Oncol. 19(2), 223-232 (2008).
78. Ellis PA, Barrett-Lee PJ, Bloomfield D et al.: Preliminary results of the UK taxotere as adjuvant chemotherapy (TACT) trial. 78 (2008).
79. Piccart M: Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer. Clin. Breast Cancer 8, S100-S113 (2008).
80. Dayam R, Grande F, Al Mawsawi LQ, Neamati N: Recent advances in the design and discovery of small-molecule therapeutics targeting HER2/neu. Expert Opin. Ther. Pat. 17(1), 83-102 (2007).
81. McIntyre JA, Castaner J, Leeson PA: Canertinib dihydrochloride: oncolytic drug HER (ErbB) inhibitor. Drugs Future 30(8), 771-779 (2005).
82. Konecny GE, Pegram MD, Venkatesan N et al.: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer. Res. 66(3), 1630-1639 (2006).
83. Xia WL, Gerard CM, Liu LH, Baudson NM, Ory TL, Spector NL: Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24(41), 6213-6221 (2005).
84. Jones SF, Burris HA, Yardley DA et al.: Lapatinib (an oral dual kinase inhibitor) plus weekly or every 3-week paclitaxel. Breast Cancer Res. Treat. 88, S64-S65 (2004).
85. Spears M, Munro AF, Mallon EA, Gullberg M, Bartlett JMS: Proc. Am. Ass. Cancer Res. 49, 3514 (2008).